Publication date: Available online 25 October 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Andrew R. Patterson, Paige Bolcas, Kristin Lampe, Rachel Cantrell, Brandy Ruff, Ian Lewkowich, Simon P. Hogan, Edith M. Janssen, Jack Bleesing, Gurjit K. Khurana Hershey, Kasper Hoebe
Abstract
Background
The GTPase of immunity-associated protein 5 is essential for lymphocyte homeostasis and survival. Recently, human GIMAP5 SNPs have been linked with an increased risk for asthma, while the loss of Gimap5 in mice has been associated with severe CD4+ T cell-driven immune pathology.
Objective
To identify the molecular and cellular mechanisms by which Gimap5-deficiency predisposes to allergic airway disease.
Methods
CD4+ T cell polarization and the development of pathogenic CD4+ T cells were assessed in Gimap5-deficient mice and a human patient with a GIMAP5 loss-of-function (LOF) mutation. House dust mite (HDM)-induced airway inflammation was assessed using a complete Gimap5 LOF (Gimap5sph/sph) and conditional Gimap5fl/flCd4Cre/ert2 mice.
Results
GIMAP5 LOF mutations in both mice and humans are associated with spontaneous polarization towards pathogenic TH17 and TH2 cells in vivo. Mechanistic studies in vitro reveal that impairment of Gimap5-deficient TH cell differentiation is associated with increased DNA damage, particularly during TH1 polarizing conditions. The DNA damage in Gimap5-deficient CD4+ T cells could be controlled by TGFβ, thereby promoting TH17 polarization. When challenged with HDM in vivo, Gimap5-deficient mice displayed an exacerbated asthma phenotype (inflammation and airway hyperresponsiveness) with increased development of TH2, TH17, and pathogenic TH17/ TH2 cells.
Conclusion
Activation of Gimap5-deficient CD4+ T cells is associated with increased DNA damage and reduced survival that can be overcome by TGFβ. This leads to a selective survival of pathogenic TH17 cells, but also TH2 in humans and mice, ultimately promoting allergic airway disease.
https://ift.tt/2PrivPu
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου